1 minute reading time (71 words)

FDA Approves First Generics of Lyrica

The U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, for the management of fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury. Full story. 

Related Posts

Want more pain resources? Check out our library of on-demand education, upcoming events, and more.

Learn More